Cancer Cell Research (Online ISSN: 2161-2609)
Current Issue
Vol.3 No.12
Article: B7-H1 Blockade Enhanced the Function of Peripheral Blood Monocyte-Derived Dendritic Cells in Patients with Bladder Cancer
by Xianglong Li, Shixiu Shao, Liran Zhai, Xuewen Guo, Haitao Niu, Yonghua Wang
Cancer Cell Research 2016 3(12) 286-289; published online 22 Octber 2016
Abstract:
To investigate B7-H1 expressions on peripheral blood
monocyte-derived dendritic cells (DCs) in patients with
bladder cancer and the effect of B7-H1 blockade on DCs
function. Monocyte-derived DCs (MoDCs) were generated from
peripheral blood mononuclear cells, which were obtained from
30 patients with bladder cancer and 10 healthy donors as
controls. The expressions of B7-H1 on MoDCs and PD-1 on
CD8+T cells were analyzed by flow cytometry. The effects of
B7-H1 blockade on MoDCs capacity of stimulating T-cell
proliferation and producing IL-10 and IL-12 were detected by
mixed lymphocyte reaction and ELISA respectively. Compared
with control, the capacity of MoDCs stimulating T-cell
proliferation was significantly decreased in patients with
bladder cancer. B7-H1 and PD-1 expressions were
significantly up-regulated on MoDCs and CD8+T cells
respectively in patients with bladder cancer. Moreover,
pre-incubation MoDCs with B7-H1 blocking mAb to block B7-H1
pathway resulted in a significant increase in T-cell
stimulated proliferation and IL-12 secretion, while a
significant decrease in IL-10 secretion. B7-H1 up-regulation
may contribute to the functional deficiency of DCs in
patients with bladder cancer, while B7-H1 blockade can
restore and enhance DCs function in patients with bladder
cancer.
Open Access Download (free) PDF
Article: Research of Expression about HIF-1α in Non-Hodgkin's Lymphoma in Children and Its Influence to Prognosis and Chemotherapy Sensitivity
by Xilin Xiong, Chaotao Zeng, Ling Liu
Cancer Cell Research 2016 3(12) 290-293; published online 22 Octber 2016
Abstract:
To explore the expression of (hypoxia-inducible factor-1α
(HIF-1α) in Non-hodgkin's lymphoma in children and its
influence in prognosis and sensitivity to chemotherapy. We
conducted immunohistochemistry to determine the expression
of HIF-1α in 125 cases of Non-hodgkin's lymphoma, and then
investigated the correlation between the expression level of
HIF-1α and the effect of preoperative chemotherapy, or
5-year survival rate. HIF-1α was highly expressed in Non-hodgkin's
lymphoma, and was unrelated to Gender, ECOG (Eastern
Cooperative Oncology Group) and IPI (international
prognostic index)score of tumor (P>0.05), but related to TNM
clinical stage, B symptoms, LDH level (P<0.05) . The
efficiency of chemotherapy in HIF-1α negative patients (90%)
was significantly higher (P<0.05) than that of HIF-1α
positive patients (68.75%). HIF-1α was highly expressed in
Non-hodgkin's lymphoma, and was closely related to lymph
node metastasis, prognosis, and sensitivity to chemotherapy.
So, HIF-1α could be one of the indicators that evaluate the
prognosis and effectiveness of chemotherapy in child with
Non-hodgkin's lymphoma.
Open Access Download (free) PDF
Article: The Influences of Chemotherapeutics on the Cell Cycle in SK-N-SH Neuroblastoma Cells and Clinic Significance
by Xilin Xiong, Ling Liu, Kai Qi, Chi Zhang, Yueqin Chen, Yang Li
Cancer Cell Research 2016 3(12) 294-298; published online 22 Octber 2016
Abstract:
This study was aimed to confirm the drug influence on cell
cycle of SK-N-SH cells by flow cytometry analysis. The SK-N-SH
cells were divided into two groups including Treatment group
and control group. All of them were given chemotherapy drugs
of ADM, CTX, VP16 and VCR, and then detected the influences
of chemotherapy drugs on the cell cycle of SK-N-SH cells by
flow cytometry instrument and. ADM: The percentage of G0/G1
phase of experimental group is (51.41±0.13)%, the percentage
of G0/G1 phase of control group is (16.59±0.52)%. CTX:The
percentage of G0/G1 phase of experimental group is
(35.19±0.69)%, the percentage of G0/G1 phase of control
group is (9.03±0.21)%. VP16:The percentage of G0/G1 phase of
experimental group is (50.25±2.06)%, the percentage of G0/G1
phase of control group is (19.33±1.12)%. DDP:The percentage
of G0/G1 phase of experimental group is (25.24±0.37)%, the
percentage of G0/G1 phase of control group is (13.51±0.39)%.
After treated with ADM, CTX, VP16 and DDP, the cell number
of G0/G1 phase is more than control group in SK-N-SH cells,
this showed significant difference (P<0.01). VCR:The
percentage of G2/M phase of experimental group is
(45.76±0.39)%, the percentage of G2/M phase of control group
is (10.95±0.36)%. The cell number of G2/M phase is more than
control group in SK-N-SH cells, this showed significant
difference (P<0.01). ADM, CTX, VP16 and DDP can
significantly arrest cell in G0/G1 phase, while VCR can
significantly arrest cell in G2/M phase.
Open Access Download (free) PDF
Article: Influencing Factor Analysis on Initial Poor Graft Function after Liver Transplantation
by Ran Tao, Bin Zhang
Cancer Cell Research 2016 3(12) 299-306; published online 7 November 2016
Abstract:
To analyze the related influencing factors for initial poor
graft function (IPGF) after liver transplantation (LT). 107
cases underwent liver transplantation from March in 2014 to
November in 2015 were selected randomly. The group of IPGF
is confirmed if ALT and/or AST are above 1500IU/L, while
non-IPGF below 1500IU/L within 72h after LT. The donor
related influencing factors includes age, source, warm
ischemic time, cold preservation time, liver biopsy at the
end of cold ischemia and if there is a supplementary
perfusion at the end of cold ischemia. The recipient related
influencing factors includes gender, age, primary liver
diseases, Child-Pugh classification, MELD score and ECOG
score. The postoperative related influencing factors include
intubation time and ICU monitoring time. There are 31 cases
(28.97%) in IPGF group and 67 cases (71.03%) in non-IPGF
group. The result of ALT and/or AST are significantly higher
in IPGF group than those in non-IPGF group (P<0.05). The
recovery time of liver function is significantly longer in
IPGF group (20.50±5.28d) than that in non-IPGF group
(13.20±5.50d) (P<0.01). The donor warm ischemic time is
significantly longer in IPGF group (4.34±2.25min) than that
in non-IPGF group (2.18±1.90min) (P<0.05). The cold
preservation time were significantly longer in IPGF group
(9.73±1.19h) than that in non-IPGF group (9.24±0.99h)
(P<0.05). There was significant difference between the 2
groups in spite of higher values in Child-Pugh C recipients’
ratio. There were no significant differences between the 2
groups (P>0.05). The rest of related influencing factors had
no significant differences between the 2 groups. Longer
donor warm ischemic time, cold preservation time and
Child-Pugh C recipients’ ration are important risks factors
for IPGF. Longer anhepatic time and rewarm ischemic time are
the potential risk factors.
Open Access Download (free) PDF